WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma

Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials

Oncolytic Viral Therapy for Malignant Pleural Mesothelioma

T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma

Immunotherapy in Malignant Pleural Mesothelioma

Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial